SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Aethlon Medical,
Inc. (Nasdaq: AEMD), a company developing medical technology to
treat cancer and life-threatening infectious disease, today
announced that it will issue financial results for its second
quarter fiscal year 2022, ended September
30, 2021, at 4:15 p.m. EST on Tuesday, November 9, 2021.
Management will host a conference call on Tuesday, November 9, 2021 at 4:30 p.m. EST to review financial results and
recent corporate developments. Following management's formal
remarks, there will be a question and answer session.
Interested parties can register for the conference by navigating
to https://dpregister.com/sreg/10161862/ef905a2ede. Please
note that registered participants will receive their dial in number
upon registration.
Interested parties without internet access or unable to
pre-register may dial in by calling:
PARTICIPANT DIAL IN
(TOLL FREE):
|
1-844-836-8741
|
PARTICIPANT
INTERNATIONAL DIAL IN:
|
1-412-317-5442
|
All callers should ask for the Aethlon Medical, Inc. conference
call.
A replay of the call will be available approximately one hour
after the end of the call through December
9, 2021. The replay can be accessed via Aethlon Medical's
website or by dialing 1-877-344-7529 (domestic) or 1-412-317-0088
(international) or Canada toll
free at 1-855-669-9658. The replay conference ID number is
10161862.
About Aethlon and the Hemopurifier®
Aethlon Medical is a biotechnology company developing the
Hemopurifier, a therapeutic blood filtration system indicated for
infectious diseases and cancer, as its lead technology. In human
studies, the Hemopurifier has demonstrated the removal of
life-threatening viruses and harmful exosomes from blood utilizing
a proprietary lectin-based technology. This action has
applications in cancer, where exosomes may promote immune
suppression and metastasis, and in life-threatening infectious
diseases.
The Hemopurifier is a U.S. Food and Drug Administration (FDA)
designated Breakthrough Device indicated for the treatment of
individuals with advanced or metastatic cancer who are either
unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in
the development or severity of the disease. Under an
Investigational Device Exemption (IDE) application, the FDA
approved a single site, open-label Early Feasibility Study (EFS) to
evaluate the Hemopurifier for reducing cancer-associated exosomes
prior to the administration of standard-of-care pembrolizumab
(KEYTRUDA®) in patients with recurrent and/or metastatic squamous
cell carcinoma of the head and neck. The EFS is being conducted at
the University of Pittsburgh Medical
Center Hillman Cancer Center.
The Hemopurifier also holds an FDA Breakthrough Device
designation and an open IDE application related to the treatment of
life-threatening viruses that are not addressed with approved
therapies. A recent amendment to the IDE enabled Aethlon to
implement a new EFS protocol to treat up to 40 COVID-19 patients at
up to 20 clinical sites in the U.S. In two case studies of patients
treated under Emergency Use (EU), the Hemopurifier demonstrated
binding of SARS-CoV-2 spike protein and removal of SARS-CoV-2 virus
from the circulation of a human patient.
Additional information can be found at
www.AethlonMedical.com.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Media Contact:
Tony Russo, Ph.D.
Russo Partners, LLC
tony.russo@russopartnersllc.com
212-845-4251
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
212-966-3650
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-to-release-second-quarter-financial-results-and-host-conference-call-on-november-9-2021-301413745.html
SOURCE Aethlon Medical, Inc.